This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Cerevel Therapeutics Class Action Lawsuit
Business class action

Cerevel Therapeutics Class Action Lawsuit

Analysis based on 11 articles · First reported Apr 18, 2025 · Last updated May 20, 2025

Sentiment
-20
Attention
3
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Coeptis Therapeutics Holdings Holdings, Inc. could lead to financial damages for the company and its controlling shareholders, Bain Capital, LP and Pfizer Inc., impacting their stock prices and reputations. Investors who sold or held Coeptis Therapeutics Holdings stock during the Class Period may be entitled to compensation, potentially affecting market sentiment towards similar M&A activities and secondary offerings.

Pharmaceuticals Biotechnology Legal Services
Event Summary

Rosen Law Firm has filed a class action lawsuit against Coeptis Therapeutics Holdings Holdings, Inc. on behalf of investors who sold or held Coeptis Therapeutics Holdings common stock between October 11, 2023, and August 1, 2024. The lawsuit alleges that Coeptis Therapeutics Holdings, along with its controlling shareholders Bain Capital, LP and Pfizer Inc., made false and misleading statements regarding a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024. It is claimed that Bain Capital, LP orchestrated the secondary offering to acquire Coeptis Therapeutics Holdings shares at a discounted price, ahead of an undisclosed acquisition by AbbVie Inc. for $45 per share, which was announced 51 days later. This alleged scheme resulted in a windfall of over $120 million for Bain Capital, LP, causing damages to other investors.

Key Actions
100 Rosen Law Firm filed class action lawsuit Coeptis Therapeutics Holdings
95 Bain Capital orchestrated secondary offering Coeptis Therapeutics Holdings
90 Coeptis Therapeutics Holdings omitted material facts
70 AbbVie agreed to acquire Coeptis Therapeutics Holdings
Entities Involved
stock
Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings is the primary defendant in the class action lawsuit, accused of making false and misleading statements regarding a secondary stock offering and its subsequent acquisition by AbbVie Inc.
Importance 100.0 Sentiment -50.0
priv
Bain Capital
Bain Capital, LP is accused of orchestrating a secondary stock offering of Coeptis Therapeutics Holdings at a deeply discounted price, allowing it to increase its position before the undisclosed acquisition by AbbVie Inc., resulting in a $120 million windfall.
Importance 90.0 Sentiment -30.0
stock
AbbVie
AbbVie Inc. acquired Coeptis Therapeutics Holdings for $45 per share, an acquisition that was allegedly undisclosed during Coeptis Therapeutics Holdings's secondary stock offering, leading to a windfall for Bain Capital, LP.
Importance 60.0 Sentiment 0.0
stock
Pfizer
Pfizer Inc. is named as a controlling shareholder of Coeptis Therapeutics Holdings, allegedly involved in orchestrating the secondary stock offering that benefited Bain Capital, LP.
Importance 50.0 Sentiment -10.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
Relationships
Coeptis Therapeutics Holdings investee ↔ Bain Capital Coeptis Therapeutics Holdings is an investee of Bain Capital, which orchestrated a secondary offering to acquire additio
Coeptis Therapeutics Holdings target ↔ AbbVie Cerevel Therapeutics Holdings agreed to be acquired by pharmaceutical giant AbbVie for $45 per share in December 2023.
Bain Capital unrelated ↔ AbbVie Bain Capital does not have a direct structural or commercial relationship with AbbVie.
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen founding partner ↔ Philip Kim Lawrence Rosen is a founding partner of the Rosen Law Firm, where he directs attorneys including Philip Kim. Together, t
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.